Considering the impact COVID-19 could have on those with multiple sclerosis, we were delighted to speak with Dr Asaff Harel (Lennox Hill Hospital, New York, NY, USA) on the subject.
1. How does multiple sclerosis (MS) increase the risk from COVID-19? (00:06)
2. What advice are you giving to patients taking disease-modifying therapies for MS, particularly cell-depleting therapies such as ocrelizumab or rituximab? (01:56)
3. In what circumstances would you advise delaying the start of MS treatment in treatment-naïve patients? (05:29)
4. What advice are you giving to patients taking steroids for MS relapses? (08:18)
5. If the pandemic lasts for months, how will you address the challenges of managing patients in the intermediate or long-term, especially those with highly active MS? (10:00)
Speaker disclosure: Dr Asaff Harel has no financial or non-financial relationships or activities to declare in relation to this video interview.
touchNEUROLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Commissioned, edited and supported by Touch Medical Media
Filmed on Thursday 9 April 2020.
Share this Video
Related Videos In Multiple Sclerosis
Patrick Vermersch, EAN 2021: Future Treatment Paradigm of Multiple Sclerosis
It was a pleasure to meet with Patrick Vermersch (University of Lille, Lille, France) to discuss the future developments expected in the treatment paradigm of multiple sclerosis. The abstract entitled: ‘BTK Inhibitor Tolebrutinib in Patients With Progressive MS: Design of Phase 3 PERSEUS and HERCULES Trials’ was presented at the 7th Congress of the European […]
Patrick Vermersch, EAN 2021: Tolebrutinib in Patients with Progressive Multiple Sclerosis: Phase 3 PERSEUS and HERCULES Trials
It was a pleasure to meet with Patrick Vermersch (University of Lille, Lille, France) to discuss the use of tolebrutinib in patients with progressive multiple sclerosis. The abstract entitled: ‘BTK Inhibitor Tolebrutinib in Patients With Progressive MS: Design of Phase 3 PERSEUS and HERCULES Trials’ was presented at the 7th Congress of the European Academy […]
Lawrence Steinman, EAN 2021: Hot Topics in Multiple Sclerosis
It was a pleasure to meet with Lawrence Steinman (Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA, USA) to discuss some of the hot topics and research trends in the field of multiple sclerosis for 2021/22. Question: What are the hot topics and latest research […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!